CoBRE for Signal Transduction and Cancer Phase III

我们的长期目标是为西弗吉尼亚州（WV）和周围的阿巴拉契亚地区建立一个NCI指定的癌症中心。西弗吉尼亚大学（WVU）是该州的旗舰大学和医学中心，目前西弗吉尼亚州没有癌症中心获得NCI认证。我们的I-II期CoBREs信号转导和癌症（P20）旨在支持基础研究开发，作为成功竞争癌症中心支持补助金（CCSG）和WVU玛丽巴布兰多夫癌症中心（MBRCC）的NCI指定的关键组成部分。我们的第一阶段和第二阶段CoBREs的具体目标从最初的重点放在初级研究人员身上，主要目标是培养职业发展和独立资助（第一阶段），到第二阶段继续支持初级研究人员，并在目标主题领域建立临界质量。此外，在第一至第二阶段期间，我们支持建立和加强基本核心设施，这一关键核心和基础设施支持的最后阶段确定了我们第三阶段（PSO）过渡奖的重点。 MBRCC中已建立的科学主题领域包括专注于EMT和转移的分子机制，乳腺癌，造血系统恶性肿瘤和移植以及转化烟草减少研究的计划。这些计划为MBRCC成员的合作和指导提供了一个结构化的氛围，并为多研究者和计划资助申请提供了平台。与此过渡奖申请相关的是，所有这些计划中的项目都得到了要求支持的核心的支持：流式细胞术，显微镜成像，动物模型和成像，蛋白质，生物统计学和生物信息学，以及生物标本处理。该第三阶段过渡奖的具体目标包括：（1）支持可持续核心设施的最先进技术和专业知识，强调可访问性和培训，我们在其中培养从事癌症相关研究的研究人员的职业发展;（2）加强MBRCC中的合作，西弗吉尼亚大学和国家将最大限度地发挥Cobre投资的影响，以确保最大限度地获得高质量，校外资助的研究所需的技术。重点放在支持合作，可持续性和避免冗余投资的战略上，以产生该奖项对MBRCC持续增长的最大影响，部分通过提供出色的核心设施支持。总的来说，这些努力支持我们的NCI指定的长期目标。

Our long term goal is to establish an NCI designated cancer center for West Virginia (WV) and the surrounding Appalachian region. West Virginia University (WVU) is the flagship university and medical center in the state with no cancer centers in WV currently having NCI designation. Our Phase I-II CoBREs for Signal Transduction and Cancer (P20) were designed to support basic research development as a .critical component of successfully competing for a Cancer Center Support Grant (CCSG) and coincident NCI designation for the WVU Mary Babb Randolph Cancer Center (MBRCC). The specific aims of our Phase I and Phase II CoBREs evolved from an initial focus on junior investigators with a primary goal of nurturing career development and independent funding (Phase I) to a combination of continued support of junior investigators with establishment of a critical mass in targeted thematic areas during Phase II. In addition, the establishment and strengthening of essential core facilities was supported during Phases I-II and the final stage of this critical core and infrastructure support defines the focus of our Phase III (PSO) Transition Award. Established scientific thematic areas in the MBRCC include Programs focused on the Molecular Mechanisms of EMT and Metastasis, Breast Cancer, Hematopoietic Malignancies and Transplantation, and Translational Tobacco Reduction Research. These Programs provide a structured atmosphere for collaboration and mentoring for the MBRCC members and the platform in which to shape multi-investigator and programmatic grant applications. Relevant to this Transition Award application, projects throughout all of these Programs are supported by the Cores for which support is requested: Flow Cytometry, Microscope Imaging, Animal Models and Imaging, Protein, Biostatistics and Bioinformatics, and Biospecimen Processing. The specific aims of this Phase III Transition Award include (1) support of state-of-the-art technology and expertise in sustainable core facilities that emphasize accessibility and training in which we nurture career development of investigators undertaking cancer related research and (2) enhanced collaboration in the MBRCC, WVU and the state to maximize the impact of CoBRE investment to ensure maximum access to technology required for high quality, extramurally funded research. Emphasis has been placed on strategies to support collaboration, sustainability, and an avoidance of redundant investment to yield the greatest impact of this award on continued growth of the MBRCC, in part, through availability of outstanding core facility support. Collectively, these efforts support our long-term goal of NCI designation.